Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial Protocol.
Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial Protocol. Future oncology (London, England) Aredo, J. V., Peled, N., Arriola, E., Wakelee, H., Ahn, M. J., Kwint, M. H., Taylor, R., van der Gronde, T., Nasirova, F., Chen, M. 2025: 1-7Abstract
ClinicalTrials.gov identifier is NCT06194448 (date of registration 5 January 2024).
View details for DOI 10.1080/14796694.2025.2587569
View details for PubMedID 41236484